Compare LAES & EIKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAES | EIKN |
|---|---|---|
| Founded | 2022 | 2019 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.9M | 316.3M |
| IPO Year | 2022 | 2026 |
| Metric | LAES | EIKN |
|---|---|---|
| Price | $0.96 | $4.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $5.88 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 3.7M | 511.7K |
| Earning Date | 09-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $59.43 | N/A |
| Revenue Next Year | $41.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $4.72 |
| 52 Week High | $5.48 | $16.50 |
| Indicator | LAES | EIKN |
|---|---|---|
| Relative Strength Index (RSI) | 27.57 | 33.10 |
| Support Level | N/A | N/A |
| Resistance Level | $2.56 | $6.82 |
| Average True Range (ATR) | 0.12 | 0.63 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 3.16 | 3.10 |
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America, while it also has its presence in Europe, Middle East & Africa, Asia Pacific, and Latin America.
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.